At ₹37 per day this weekly insulin replaces 365 injections

The Essentials

• Awiqli is a long-acting basal insulin designed to be injected just once every seven days.
• A standard 70-unit weekly dose costs approximately ₹261, bringing the daily expense to roughly ₹37.
• Patients eliminate 313 injections per year while maintaining steady overnight and between-meal blood sugar levels.

The Pulse

Novo Nordisk India addresses a massive psychological barrier in diabetes management by introducing a once-weekly injection schedule. Needle fatigue remains one of the primary reasons adults delay starting essential insulin therapy, often risking long-term complications. By cutting the injection frequency by 85 percent, Awiqli alters how patients and doctors approach basal insulin prescriptions.

For Indian buyers evaluating the switch, the financial context matters as much as the physical relief. The pricing sits aggressively below existing premium daily analogue insulins, which typically cost between ₹345 and ₹453 per week.

To scale this nationally, the Danish pharmaceutical company has aligned with local infrastructure. Shantha Biologics handles the local formulation and cartridge filling, while Abbott India manages commercial distribution. This ensures immediate availability across major pharmacies for adults managing both Type 1 and Type 2 diabetes, particularly those whose glucose levels no longer respond to oral medication alone.

The Breakdown

The drug, holding the generic name insulin icodec, relies on data from the global ONWARDS Phase 3 clinical trials, which actively included Indian participants. Efficacy metrics demonstrate superior long-term blood sugar reduction, measured through HbA1c levels, and significantly better Time in Range compared to daily basal insulins.

Safety protocols remain identical to traditional treatments, with hypoglycemia being the primary side effect requiring standard medical supervision. The liquid formulation is delivered via pre-filled FlexTouch pen devices, requiring no manual drawing from vials. It is available in two capacities: a 1 ml pen holding 700 units and a 3 ml pen holding 2,100 units.

The Distinction

The primary differentiator of Awiqli is its molecular binding architecture. Competing basal insulins require daily administration to maintain stable glucose levels in the bloodstream. This formulation modifies the insulin molecule with a specific fatty acid chain that binds securely to albumin upon injection. This creates an inactive, subcutaneous reservoir. The bond then reverses at a steady, controlled rate over seven days to deliver a uniform stream of active insulin. This structural mechanism reduces the standard diabetes management burden from 365 yearly injections to exactly 52.

The Snapshot

Specification	Detail
Medicine Name	Awiqli (insulin icodec)
Manufacturer	Novo Nordisk India
Type	Long-acting (basal) insulin
Dosing Frequency	Once every seven days
Target Demographic	Adults (18+) with Type 1 & Type 2 diabetes
Price (1 ml FlexTouch)	₹2,611 (700 units)
Price (3 ml FlexTouch)	₹7,833 (2,100 units)
Average Daily Cost	~₹37 (based on 70 units/week)
Availability	Immediate across India

The Big Picture

Daily basal insulins have dominated the Indian diabetes care market for decades, with patients historically accepting the daily prick as an unavoidable reality of managing their condition. A shift to a weekly delivery system forces competitors to rethink patient compliance metrics. By demonstrating superior Time in Range over daily analogues during clinical trials, this introduction establishes a new baseline expectation for what long-term glucose management should look like in practice.

The India Prospective

At roughly ₹261 per week for a standard dose, this treatment actively undercuts several premium daily insulins currently dominating the Indian market. Localised manufacturing through Shantha Biologics ensures the supply chain can handle domestic volume without import delays. For the urban Indian patient juggling a heavy commute and extended work hours, calculating injection timing on daily travels is no longer a mandatory routine.

The Inside Intel

The slow-release mechanism works because the modified insulin specifically targets and attaches to albumin, a highly common protein naturally circulating in human blood. Instead of fighting the body’s natural chemistry, the drug uses this native blood protein to create a temporary, inactive storage depot right under the skin, releasing the active medicine only as the albumin bond slowly breaks down.

The Unboxed Truth

Unbox Daily HQ considers this the most practical advancement in diabetes care available in India right now, not just because of the clinical data, but because it actively removes the anxiety of daily injections while reducing the overall monthly expense.

For a 45-year-old corporate manager in Mumbai who travels frequently and struggles to maintain a consistent daily injection schedule across different time zones, the logistics of diabetes management just became exponentially easier. At ₹2,611 for a 700-unit pen, the math works directly in the patient’s favour. Costing roughly ₹261 per week for a standard 70-unit dose, it sits comfortably below the ₹345 to ₹453 weekly cost of premium daily alternatives. This is rare in healthcare, a clinical upgrade that improves the daily routine without demanding a price premium. The structural shift from relying on manual daily administration to an automated, albumin-bound weekly release mechanism makes this an immediate step up from any daily basal insulin currently prescribed.

Best for: A working professional requiring long-acting insulin who frequently travels or struggles with the mental fatigue of a daily injection routine

Who Is This For: Perfect for 35 to 65-year-old adults managing Type 1 or Type 2 diabetes in active urban environments who need consistent blood sugar regulation without the interruption of daily medical administration

The Checkout

Novo Nordisk India Corporate Portal

The Source

Novo Nordisk India

The Query